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Abstract
Background: Intensity values measured by Affymetrix microarrays have to be both normalized,
to be able to compare different microarrays by removing non-biological variation, and summarized,
generating the final probe set expression values. Various pre-processing techniques, such as dChip,
GCRMA, RMA and MAS have been developed for this purpose. This study assesses the effect of
applying different pre-processing methods on the results of analyses of large Affymetrix datasets.
By focusing on practical applications of microarray-based research, this study provides insight into
the relevance of pre-processing procedures to biology-oriented researchers.
Results: Using two publicly available datasets, i.e., gene-expression data of 285 patients with Acute
Myeloid Leukemia (AML, Affymetrix HG-U133A GeneChip) and 42 samples of tumor tissue of the
embryonal central nervous system (CNS, Affymetrix HuGeneFL GeneChip), we tested the effect
of the four pre-processing strategies mentioned above, on (1) expression level measurements, (2)
detection of differential expression, (3) cluster analysis and (4) classification of samples. In most
cases, the effect of pre-processing is relatively small compared to other choices made in an analysis
for the AML dataset, but has a more profound effect on the outcome of the CNS dataset. Analyses
on individual probe sets, such as testing for differential expression, are affected most; supervised,
multivariate analyses such as classification are far less sensitive to pre-processing.
Conclusion: Using two experimental datasets, we show that the choice of pre-processing method
is of relatively minor influence on the final analysis outcome of large microarray studies whereas it
can have important effects on the results of a smaller study. The data source (platform, tissue
homogeneity, RNA quality) is potentially of bigger importance than the choice of pre-processing
method.
Background
The analysis of gene expression data generated by micro-
arrays, such as the high-density oligonucleotide micro-
arays produced by Affymetrix (Santa Clara, CA), is an
often laborious process in which a basic understanding of
molecular biology, computer science and statistics is
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required. In a typical microarray experiment, RNA
obtained under various conditions (patients, treatments,
disease states etc.) is hybridised to microarrays. By tagging
the RNA with a fluorescent marker, intensity values can be
obtained that correspond to the amount of labeled RNA
bound to the array. On the widely used Affymetrix plat-
form, gene expression is measured using probe sets con-
sisting of 11 to 20 perfect match (PM) probes of 25
nucleotides, which are complementary to a target
sequence, and a similar number of mismatch (MM)
probes in which the 13th nucleotide has been changed.
The MM probe measurements are thought to comprise
most of the background cross-hybridization and stray sig-
nal affecting the PM probes.
Normalization of probe intensity values is performed to
remove any non-biological variation. The individual
probe measurements are then summarized as probe set
expression levels, as estimates of the amount of specific
mRNA present in the biological sample. Normalization
and probe set summarization are statistical procedures for
which several methods have been developed. MicroArray
Suite (MAS 5.0), a software package provided by Affyme-
trix, normalizes intensities using a global scaling proce-
dure and measures expression using a one-step Tukey
biweight algorithm, which is defined as the anti-log of a
robust average of differences between log(PM) and
log(MM) [1]. The same algorithms are implemented in
the software package currently provided by Affymetrix,
GCOS. One of the first alternatives to this approach was
provided by Li and Wong with the dChip-method, which
scales the intensity data towards the median intensity in a
group of arrays and then uses model-based index esti-
mates, giving variable weight to PM-MM probe pairs of a
probe set based on variance between arrays, to measure
expression [2]. Irizarry et al. introduced RMA (robust
multi-array average), later followed by GCRMA (GC
robust multi-array average). RMA, often preceded by
quantile normalization [3,4], applies a median polish
procedure to PM intensities only in summarization.
GCRMA is based on a similar model as RMA but takes into
account the effect of stronger bonding of G/C pairs [5,6].
An overview of these methods is shown in Table 1. Other
normalization methods, such as the variance stabilizing
normalization (VSN, [7]) and summarization methods,
such as PLIER [8], have been developed, but are less fre-
quently applied.
Various studies have been published which assess the dif-
ferences in outcome of these different data pre-processing
methods [9-14]. To validate and test pre-processing meth-
ods, two publicly available datasets are commonly used.
The Latin square dataset provided by Affymetrix [15] con-
tains spiked-in cRNA's at several concentrations facilitat-
ing the assessment of the relation between mRNA
concentration and expression value. The GeneLogic dilu-
tion series (obtainable on request, [16]) gives an estimate
of the relation between actual and measured differential
expression. Based on these datasets, an online benchmark
tool has been developed to encourage authors to test their
method [17]. This tool assesses quality of pre-processing
using several parameters in five different groups: (1) vari-
ability of expression across replicate arrays, (2) response
of expression measure to changes in abundance of RNA,
(3) sensitivity of fold-change measures to the amount of
actual RNA sample, (4) accuracy of fold-change as a meas-
ure of relative expression and (5) usefulness of raw fold-
change score for the detection of differential expression.
Pronounced differences between different procedures
have been shown to occur [4,9,11,13].
The studies on the Latin square and dilution data were
performed using data generated specifically for this pur-
pose, allowing comparisons of specific analyses, showing
accurately which methods perform best. In effect, statisti-
cal properties of the various estimators are tested. Several
authors noted that the use of two special-purpose datasets
for calibration of statistical procedures creates a risk on
Table 1: Overview of several pre-processing methods.
Normalization method Summarization method
MAS Global scaling – individual array normalization; moderate influence 
on expression levels, no effect on outliers. Non-parametric 
methods are potentially more reliable
Tukey biweight (robust average) – subtract MM from PM and 
adjust for negative values
dChip Average median scaling – individual array normalization; moderate 
influence on expression levels, no effect on outliers. Non-
parametric methods are potentially more reliable
Model-based index estimate – subtract MM from PM, but take 
indivual probe variability, assessed over all available arrays, into 
account
RMA Quantile normalization – multiple array normalization; 
considerable influence on expression levels, with removal of 
outliers. Parametric methods are potentially more reliable
Median polish – only use MM for background adjustment; fit 
parameters of linear model robustly using median polish, taking 
into account all available arrays
GCRMA Quantile normalization – multiple array normalization; 
considerable influence on expression levels, with removal of 
outliers. Parametric methods are potentially more reliable
Median polish – only use MM for background adjustment; fit 
parameters of linear model robustly using median polish, taking 
into account all available arrays; fit extra GC-content parameterBMC Bioinformatics 2006, 7:105 http://www.biomedcentral.com/1471-2105/7/105
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overfitting of the available data and therefore focused on
using experimental data to compare methods with respect
to the sets of differentially expressed genes found
[9,11,14]. This sometimes lead to contradictory results,
where for instance a study using the Latin square dataset
showed the MAS5.0 method to outperform the dChip
method on detecting differentially expressed genes [13],
while a study on experimental data showed the opposite
[9]. Therefore, more work is needed to reliably establish
how important the effect of choice of pre-processing
method is in every-day practice, especially when analyses
such as clustering and classification are applied.
In this paper, we focus on one practical application of
microarrays: patient-cohort studies [18-22]. In such stud-
ies, researchers typically select sets of genes that are differ-
entially expressed between certain known conditions, a
supervised analysis. Moreover, unsupervised techniques
(not imposing any prior knowledge on the data) such as
clustering are applied to detect biological relations
between samples or genes by grouping them according to
their expression profiles. Often the goal is to obtain a pre-
dictor (classifier) for, for instance, prognostically relevant
categories, using supervised analysis.
Given that different pre-processing procedures will influ-
ence the outcome of these analyses, several questions can
be asked, such as: How well is expression measured using
a number of different pre-processing methods? What is
their effect on the detection of differentially expressed
genes, clusters found and classification results? By focus-
ing on practical applications of microarray studies, we
hope to give insight into the relevance of different pre-
processing procedures to biology-oriented researchers.
Results and discussion
The aim of our work was to evaluate the effect of several
microarray data pre-processing methods on the outcome
of analyses commonly applied in patient-cohort studies.
Four types of analysis were performed: (1) expression
level measurement, (2) detection of differential expres-
sion (supervised), (3) cluster analysis (unsupervised) and
(4) classification of samples (supervised). These analyses
were applied to two publicly available datasets, one of
285 acute myeloid leukemia (AML) samples profiled on
Affymetrix HG-U133A GeneChips [19] and one consist-
ing of 42 Affymetrix HuGeneFL GeneChips hybridized
with central nervous system (CNS) tumor tissue [22].
Comparing expression levels to RT-PCR (AML dataset)
Pearson correlation coefficients between expression levels
of EVI1, CEBPA, MEIS1, HOXA7, HOXA9, TRKA, PRDM1,
PRDM2, P8 and GMCSF found in the AML dataset, meas-
ured by RT-PCR and microarray after pre-processing using
different methods, are listed in Table 2. The actual expres-
sion levels measured by RT-PCR and the Affymetrix probe
sets (using the different pre-processing methods) are
listed in Supp. Table 2 (see Additional file 1). Average cor-
relation to RT-PCR expression is 0.48–0.57 for the differ-
ent methods with RMA (0.57 ± 0. 30) and GCRMA (0.57
± 0.28) showing the highest correlation on average, dChip
(0.48 ± 0.31) scoring lowest and MAS (0.52 ± 0.29) scor-
ing intermediate. No significant differences have been
found between correlations of different pre-processing
methods and RT-PCR data and (taking RT-PCR as gold
standard) no pre-processing method unequivocally per-
formed best in measuring expression level. Correlation
overall is moderate, but this result is likely to be influ-
enced by different genomic location of RT-PCR primers
and Affymetrix probes, resulting in different expression
values when alternative splicing occurs; by incorrect anno-
tation of individual probe sets (such as 206848_at); and
by suboptimal RT-PCR primer and Affymetrix probe
design.
Comparing expression levels between pre-processing 
methods
Correlations are depicted in Figure 1A for the AML dataset
and in Figure 1B for the CNS dataset for each probe set
present on the microarray, ordered by average expression
level over the four differently pre-processed datasets.
Overall, a clear trend of increasing correlation at increas-
ing expression levels is apparent, which has been noticed
before [17]. Aside from a dense area of highly correlated
genes with intermediate to high expression, in several
comparisons, for instance that of RMA to MAS, a second
more densely populated area is visible in the range of
extremely low expression levels. These expression levels
correspond to non-expressed genes (40–50% of all probe
sets). At these levels, variability is relatively higher, result-
Table 2: Correlation between expression levels measured by RT-
PCR and Affymetrix GeneChip on the AML dataset, after use of 
different pre-processing methods.
Gene symbol Probe set ID MAS dChip RMA GCRMA
EVI1 215851_at 0.34 0.52 0.63 0.29
221884_at 0.64 0.87 0.88 0.45
P8 209230_s_at 0.09 0.15 0.16 0.00
PRDM1 217192_s_at 0.53 0.57 0.55 0.53
TRKA 208605_s_at 0.66 0.77 0.75 0.63
PRDM2 205277_at 0.21 0.25 0.28 0.25
203057_s_at 0.56 0.56 0.59 0.58
203056_s_at 0.57 0.59 0.59 0.55
216433_s_at 0.33 0.42 0.45 0.12
MEIS1 204069_at 0.88 0.90 0.90 0.86
HOXA9 214651_s_at 0.90 0.90 0.91 0.89
209905_at 0.91 0.91 0.90 0.90
HOXA7 206847_s_at 0.80 0.77 0.80 0.89
206848_at 0.01 0.02 0.02 0.04
CEBPA 204039_at 0.61 0.61 0.63 0.58
GMCSF 210229_s_at 0.20 0.32 0.10 0.15BMC Bioinformatics 2006, 7:105 http://www.biomedcentral.com/1471-2105/7/105
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ing in moderate correlations. As the normalization
method of RMA and GCRMA is the same (both using MM
probes only for background correction) and their summa-
rization methods are very similar, it is not surprising that
these methods show the highest resemblance in measured
expression. However, they show more agreement with
MAS than with dChip (which was also seen when compar-
ing microarray expression levels to RT-PCR expression lev-
els). Perhaps this has to do with the fact that dChip
calculates expression on the original probe intensity val-
ues rather than the log-transformed ones used by the
other methods.
The CNS dataset shows similar trends, but the much
higher level of variation suggests that sample size and/or
quality of the platform and biological sample have a
much more profound effect on estimated expression lev-
els, than has the pre-processing method.
In conclusion, the AML dataset shows that variation in
estimated expression levels exists between different pre-
processing methods and that this variation is higher at
lower mRNA concentrations. The clear trend of increasing
correlation with increasing expression level suggests that
pre-processing has an influence, but this concerns only a
minority of probe sets.
Using the Affymetrix Latin square dataset, Rajagopalan
noted that MAS and dChip perform equally well on esti-
mating expression levels, with a small non-significant
advantage for MAS [13]. Although trends towards MAS
seem visible in our study as well, MAS and dChip behave
rather differently in the experimental dataset used here.
Testing not only the Latin square dataset but also the
GeneLogic dataset, Irizarry et al. conclude that RMA
shows highest sensitivity and specificity when compared
to dChip and the AvDiff algorithm [10]. As no method
performs significantly different in our study, these results
are not confirmed
Differential expression
Significance of differences in expression when comparing
two conditions was calculated using three standard meth-
ods: the t-test; the Wilcoxon rank sum test, controlling the
Family-Wise Error Rate (FWER); and Significance Analysis
of Microarrays (SAM), a test controlling the False Discov-
ery Rate (FDR) using a statistic resembling that of the t-test
[23]. Different pre-processing methods were compared by
assessing the overlap in the number of probe sets marked
as differentially expressed by two pre-processing methods.
We call a probe set differentially expressed below an
FWER or FDR of 5%. In the AML-dataset, p-values (FWER)
and  q-values (FDR) were computed for samples with
recurrent FLT3 ITD mutations vs. the rest, inv(16) vs. the
rest, t(15;17) vs. the rest and t(8;21) vs. the rest. In the
CNS-dataset,  p-values and q-values were computed for
Correlation of expression values pre-processed by two  methods Figure 1
Correlation of expression values pre-processed by 
two methods. Pearson correlation coefficients of expres-
sion measurements calculated by two pre-processing proce-
dures are shown on the y-axis, probe sets ranked by average 
expression level over the four pre-processing methods are 
shown on the x-axis. Contours indicate equal density, as esti-
mated using a Gaussian kernel density estimate, with kernel 
width optimised by leave-one-out maximum-likelihood. A. 
AML dataset. B. CNS dataset.BMC Bioinformatics 2006, 7:105 http://www.biomedcentral.com/1471-2105/7/105
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PNET-, RHAB-, GLIO- and MED-samples vs. the rest,
respectively. Although different subdivisions into condi-
tions were thus compared, the outcomes are remarkably
similar.
Considering the AML dataset, the overlap between the
probe sets selected on RMA and GCRMA pre-processed
data is most striking, with a minimum R of 0.78 (average
0.85, Table 3, Supp. Tables 3A–C9 (see Additional file 1).
Overall, the overlap between different pre-processing
methods is considerable: a minimum R of 0.56 (average
0.74) is found, independent of the statistical test used.
The combination MAS-dChip comes up as least compara-
ble (Table 3, Supp. Tables 3A–C (see Additional file 1)).
MAS shows higher concordance with RMA and GCRMA
than does dChip. No indications were found that R will
increase for smaller FWER or FDR (data not shown).
The overlap between probe set lists detected as differen-
tially expressed is considerably less in the CNS dataset
than in the AML dataset and there is more variation,
which could be due to the higher amount of noise in this
dataset and/or its smaller sample size. +The RMA-GCRMA
comparison results in an average R of 0.56 (Table 4, Supp.
Tables 3D–F (see Additional file 1)). Again, pre-process-
ing with MAS will result in less differences with RMA pre-
processing than with dChip (Table 4, Supp. Tables 3D–F
(see Additional file 1)). Overall, average R is 0.40 for this
dataset. When using q-values, again RMA and/or MAS
often detect larger numbers of differentially expressed
probe sets than dChip and GCRMA. Note also that the dif-
ference between the number of probe sets selected using
the t-statistic and the Wilcoxon statistic is larger than for
the AML dataset. This may be caused by outlier data on the
HuGeneFL microarrays, to which the t-test is more suscep-
tible.
In a study evaluating experimental datasets of 79 ovary
tumors and 47 colon tumors profiled on the Affymetrix
HG-U133A platform, Shedden et al. [9] show that dChip
results are closer to those obtained using RMA than to
those obtained using MAS, an observation not confirmed
by our results. Statistical tests on RMA and MAS pre-proc-
essed data detect the largest number of differentially
expressed probe sets in most cases, where GCRMA and
dChip select less, with a maximum difference in number
of selected probe sets of 49.7% in the AML dataset (Supp.
Table 3A (see Additional file 1), q-values). This does not
confirm the observations of Shedden et al., who found
that dChip outperformed MAS and GCRMA in terms of
sensitivity. Irizarry et al. [10] report that RMA performs
better than dChip and the AvDiff algorithm in finding
truly differentially expressed genes. No statement on the
true nature of probe sets measured as differentially
expressed here can be made. However, MAS and RMA
score roughly equal numbers of probe sets as differentially
expressed and both methods find more probe sets to be
differentially expressed than dChip and GCRMA, as in
[10].
Recently, Hoffmann et al. [11] stated that normalization
will have a larger influence on the number of differentially
expressed genes than the actual statistical test used.
Although a direct comparison of [11] and our work is not
possible due to differences in multiple testing correction,
in our (much) larger datasets we observe a larger differ-
ence between the number of probe sets selected as a result
of the multiple testing correction used (FWER or FDR)
than as a result of the choice of pre-processing method.
Overall, the overlap between sets of genes selected as dif-
ferentially expressed is considerable when pre-processing
the data using different methods and overlap increases
when non-biological variation decreases. Using the cur-
rent datasets, it is not possible to give indications of the
quality of probe sets selected, due to the lack of ground
truth.
Cluster analysis
Data resulting from different pre-processing methods was
clustered by k-means (KM) and hierarchical clustering
with single, average and complete linkage (HC/S, HC/A,
HC/C). Clusterings of both the AML and CNS datasets
were compared using the Jaccard index; results are shown
in Figure 2 and Supp. Figure 1 (see Additional file 1) [24].
RMA and GCRMA results are often similar, which is to be
Table 3: Overlap R(A, B) between sets of genes marked as 
differentially expressed after pre-processing with different 
methods. p- and q-values for the significance of difference in 
expression between samples from the AML dataset with 
recurrent FLT3 mutation and samples without recurrent FLT3 
mutation were calculated. The numbers on the diagonal 
represents the number of probe sets marked as differentially 
expressed after application of each method.
MAS dChip RMA GCRMA
SAM q-values MAS 3185
dChip 0.68 2973
RMA 0.72 0.72 3649
GCRMA 0.73 0.70 0.86 3650
t-test p-values MAS 458
dChip 0.66 354
RMA 0.68 0.70 419
GCRMA 0.69 0.71 0.83 472
Wilcoxon test p-values MAS 337
dChip 0.72 295
RMA 0.75 0.79 322
GCRMA 0.75 0.79 0.87 344BMC Bioinformatics 2006, 7:105 http://www.biomedcentral.com/1471-2105/7/105
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expected. dChip results frequently differ from results
obtained using other pre-processing methods. In general,
KM, HC/A and HC/C on both datasets show Jaccard indi-
ces of 0.3–0.6. HC/S shows higher indices, but the actual
resulting clusterings are very poor due to the well-known
high susceptibility of this method to outliers (data not
shown): almost all samples end up in a single cluster, the
remaining samples form individual clusters.
Jaccard indices of clustering results Figure 2
Jaccard indices of clustering results. Results were obtained using correlation distance on a fixed number of probe sets, 
after different pre-processing procedures and by different clustering algorithms. A. AML dataset, k = 12 clusters, 3000 probe 
sets. B. CNS dataset, k = 5 clusters, 1000 probe sets.BMC Bioinformatics 2006, 7:105 http://www.biomedcentral.com/1471-2105/7/105
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As an example, the confusion matrix in Table 5 shows that
many clusters found using the MAS pre-processed dataset
are also found reasonably well using the RMA pre-proc-
essed dataset (by k-means clustering into k = 12 clusters,
on correlation distance, using 3000 probe sets). However,
as there are 2716 sample pairs co-occurring in a cluster in
both clustering results, 1099 sample pairs co-occurring in
a cluster in the MAS clustering result only and 1137 sam-
ple pairs co-occurring in a cluster in the RMA result only,
this leads to a Jaccard-index J of only 2716/(2716 + 1099
+ 1137) = 0.55.
In an attempt to quantify the sensitivity of clusterings
found to small perturbations, stability-normalized Jaccard
indices JSN were therefore calculated, indicating to what
extent the Jaccard indices J found are out of the ordinary.
Figure 3A illustrates that for KM and the pair of pre-
processing methods used (MAS and RMA), J  = 0.55 is
actually better than the Jaccard index obtained on average
on a slightly changed version of the MAS pre-processed
dataset (JSN > 0.5), but worse than that obtained on aver-
age on a slightly changed version of the RMA pre-proc-
essed dataset (JSN < 0.5).
Figure 3B shows that for KM and HC/A, differences using
MAS and (GC)RMA are actually roughly of the same order
as differences between 90% subsamples of the MAS pre-
processed dataset (i.e. the JSN is high for MAS). To a lesser
extent, this also holds for dChip vs. (GC)RMA. However,
these same differences are quite large in terms of the dif-
ferences in clusterings between 90% subsamples of
(GC)RMA (i.e. the JSN is low for (GC)RMA). The main
cause for this is (GC)RMA's higher stability: as it normal-
ises over all arrays – unlike MAS and dChip – leaving out
a small subset will have only a limited effect on probe set
distributions, and hence on clustering results. When RMA
and GCRMA results are compared to each other, a high JSN
results as well. HC/C oftens shows lower values for J and
JSN.
The CNS dataset (Figure 3C) largely tells the same story,
although the JSN are somewhat larger, especially for k-
means clustering. This is due to the smaller sample size:
Stability normalization of Jaccard index Figure 3A
Stability normalization of Jaccard index. Illustration of 
stability normalization for the Jaccard index of a particular k-
means clustering (k = 12), obtained on MAS- and RMA-pre-
processed versions of the AML dataset (correlation distance, 
3000 probesets). The dotted line corresponds to the Jaccard 
index between these clusterings (0.55). For both MAS and 
RMA, the CDF can be used to arrive at a stability normalized 
Jaccard index; in this case 0.90 and 0.16. The arrows indicate 
the Jaccard indices for which the normalised Jaccard index JSN 
= 0.5. The interpretation is that for MAS, the comparison to 
RMA falls well within what can be expected, for RMA less so.
Table 4: CNS dataset, GLIO samples vs. others.
MAS dChip RMA GCRMA
SAM q-values MAS 400
dChip 0.39 714
RMA 0.50 0.54 666
GCRMA 0.52 0.39 0.58 330
t-test p-values MAS 224
dChip 0.36 303
RMA 0.43 0.51 159
GCRMA 0.47 0.37 0.55 123
Wilcoxon test p-
values
MAS 17
dChip 0.41 17
RMA 0.46 0.29 18
GCRMA 0.45 0.26 0.5 14BMC Bioinformatics 2006, 7:105 http://www.biomedcentral.com/1471-2105/7/105
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leaving out 10% of the samples relatively has more impact
on the Jaccard indices.
Supp. Figures 1 and 2 (see Additional file 1) illustrate the
influence of the choice of the number of clusters (k) and
the distance measure (correlation or Euclidean). Both
datasets show the same effects. For lower k (k = 2), both
Jaccard indices and stability-normalized Jaccard indices
are much higher, as clusterings of data pre-processed by
the various methods agree on structure clearly present in
the data. For higher k (AML: k = 20, CNS: k = 10), Jaccard
indices and stability-normalized Jaccard indices are simi-
lar to or even lower than those for the k chosen originally.
Using Euclidean distance leads to slightly lower Jaccard
indices, with an increase in difference between Note how-
ever the more pronounced differences between how
dChip and other methods. This may be the result of the
negative values it produces (unlike MAS and (GC)RMA),
which are thresholded at 0.1 in the data transformation
steps. Due to the centering by the geometric mean this can
lead to larger extreme probe set values over arrays.
In conclusion, clustering results are sensitive to the choice
of pre-processing method. This sensitivity is smallest for
small numbers of clusters k (i.e. when looking for clearly
present structure) and when using correlation distance.
Additionally, using (GC)RMA seems to result in more sta-
ble clusterings than using MAS or dChip.
Classification
A number of different classification problems defined on
the datasets have been approached using several classifiers
trained on data of all pre-processing methods. Resulting
performances are listed in Tables 6, 7, 8, 9 and Supp. Table
4 (see Additional file 1). Results are reported only for the
number of probe sets giving lowest average test set error
over the four methods. Although this makes the perform-
CNS dataset: stability-normalized pairwise Jaccard indices of cluster labels assigned by the various methods Figure 3C
CNS dataset: stability-normalized pairwise Jaccard indices of cluster labels assigned by the various methods. 
Clusterings into k = 5 clusters obtained using correlation distance on 1000 probe sets. Legend is shown in Figure 3D. For k-
means, the grey bars indicate standard deviation over 10 repeated experiments.
AML dataset: stability-normalized pairwise Jaccard indices of cluster labels assigned by the various methods Figure 3B
B: AML dataset: stability-normalized pairwise Jaccard indices of cluster labels assigned by the various meth-
ods. Clusterings into k = 12 clusters obtained using correlation distance on 3000 probe sets. Legend is shown in Figure 3D. 
For k-means, the grey bars indicate standard deviation over 10 repeated experiments.BMC Bioinformatics 2006, 7:105 http://www.biomedcentral.com/1471-2105/7/105
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ance estimates biased, it does not influence comparison
between methods.
In the AML dataset, inversion of chromosome 16 is well
predictable, with error rates smaller than 5% (Table 6).
Differences in error rate between classification algorithms
are very small: although the nearest centroid classifier
often performs worst, no algorithm performs significantly
better than others. More importantly, no pre-processing
method scores significantly better or worse than others
(although MAS relatively often shows best results).
Although predicted with a higher error rate, these observa-
tions are confirmed on the FLT3 (Table 7) and CCR (Table
8) AML problems.
Interestingly, this also holds for the CNS dataset (Table 9
shows results for the MED problem; other results are
shown in Supp. Table 4 (see Additional file 1)), although
performances show much more variation and MAS no
longer comes out best. Ofcourse, the CNS dataset is rather
small, so obtaining good classifiers is harder.
No classifier or pre-processing method scores significantly
better than others. This can be explained by the fact that
the probe sets on which classification is based are already
selected to give good classification results: on differently
pre-processed datasets, different probe sets may be
selected (in fact, the selected sets of n = 1000 probe sets
show an overlap of 71% to 87%). The six classifiers used
seem to be equally susceptible to different pre-processing
methods; that is, for each of them performance varies with
pre-processing method used in at least some of the prob-
lems.
For classification, the choice of pre-processing method
(and, for that matter, classification algorithm) seems to be
irrelevant.
Conclusion
Patient-cohort studies using microarrays are often per-
formed to find pathobiologically relevant relations
between genes and patient classes. The Affymetrix plat-
form has become increasingly popular for this type of
study. Processing intensity values obtained using Affyme-
trix GeneChips remains a challenging task for many
microarray researchers. Apart from the Affymetrix MAS
procedure, several statistical procedures have been pro-
posed to assess expression, such as dChip, RMA and
GCRMA. Our study has tried to estimate the effects of the
choice of pre-processing method from a practical view-
point. To this end, we have applied a number of analyses
to two datasets, which we believe to represent two
extremes in recent patient-cohort studies both in terms of
sample size and of platform used.
D: Legend to markers in Figures 3B-C Figure 3D
D: Legend to markers in Figures 3B-C.
Table 5: Confusion matrix of MAS and RMA clustering results. Clustering into k = 12 clusters was performed using k-means clustering, 
using correlation distance on 3000 probe sets. A cell at position (i, j) shows the number of samples assigned to cluster i on data pre-
processed using MAS and to cluster j on data pre-processed using RMA. The Jaccard index between these two clusterings is 0.55.
Number of samples in RMA clusters
123456789 1 0 1 1 1 2
N u m b e r  o f  s a m p l e s  i n  M A S  c l u s t e r s 1 3 3 11011100110
2 0 3 3 0010000020
3 03 2 8 200000000
4 007 2 4 01010000
5 0100 2 1 2000000
6 00130 2 1 000000
7 000000 2 1 00000
8 0001000 1 8 0000
9 00004000 1 0 008
1 0 000000001 1 0 00
1 1 0300000000 1 0 0
1 2 001000007000BMC Bioinformatics 2006, 7:105 http://www.biomedcentral.com/1471-2105/7/105
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The experimental results indicate that the normalization
step in (GC)RMA has a larger effect on the data than the
one in MAS and dChip, but this cannot be separated from
the effect of applying different models for summarization.
And, although the dChip and RMA summarization mod-
els are more related to each other than the MAS and RMA
ones, MAS pre-processed data shows more similarity to
RMA than does dChip.
In practical terms, the question of which method will give
expression value estimates closest to the actual data is still
to be answered; this study has not attempted to answer it,
because we have not used data with accompanying
ground truth. We showed that results of various analyses
are not always dependent on the choice of pre-processing
method. Analyses such as calculating expression levels or
assessing differential expression are reasonably suscepti-
ble to differences between pre-processing methods; clus-
tering as well, except when looking for clearly present
structure (that is, using a small number of clusters); but
classification far less so. The message is that while care
should be taken in assigning biological meaning to indi-
vidual probe set measurements, this holds less for global
statements about the data.
Several other studies have been performed to assess the
level of concordance in differential gene sets between pre-
processing methods and noted that the choice of the
method was of major influence, with different studies
favoring different pre-processing methods [9,11,13]. Our
results do not conclusively confirm one or more studies,
although results partially overlap. One major difference
with other studies is the size of the used datasets, where
one of the datasets used in this study is considerably
larger. It is to be expected that with the evolution of the
array technology, the number of profiled samples in any
single patient-cohort study is likely to increase.
The effects of the choice of pre-processing method are far
more profound in the CNS dataset than in the AML data-
set. Several possible explanations can be given for this, but
it is not possible to single any of them out based only on
the two datasets used in this study. The AML dataset con-
tains more samples, which allows for better parameter
estimates in the analysis methods presented in this work.
Furthermore, Affymetrix technology has evolved over
time, resulting in a more stable platform for the AML data-
set (HG-U133A) than the CNS dataset (HuGeneFL). Bio-
logical differences also play a role in the two datasets. The
amount of viable cells obtained from bone marrow is also
likely to be higher compared to solid tumors, which often
show necrotic areas, leading to difference in RNA-quality
and -degradation. Also, tumor cells can be purified from
bone marrow samples using Ficoll-centrifugation, a tech-
nique which is not available for the solid tumors which
were hybridized in the CNS dataset, resulting in less con-
tamination with other cell types in hybridized samples,
which is known to be an important factor [25]. We recom-
mend that the emphasis in setting up a large microarray-
based study should therefore be on the quality of the bio-
Table 7: AML dataset, FLT3 problem.
MAS dChip RMA GCRMA
Classifier NC (10) 0.16 (0.06) 0.19 (0.09) 0.16 (0.08) 0.26 (0.08)
(number of probe sets used) PAM (20) 0.14 (0.06) 0.14 (0.06) 0.14 (0.06) 0.14 (0.06)
LIKNON (20) 0.12 (0.05) 0.11 (0.05) 0.12 (0.06) 0.13 (0.05)
k-NN (200) 0.10 (0.05) 0.11 (0.05) 0.11 (0.06) 0.13 (0.06)
SVC/P (20) 0.12 (0.05) 0.11 (0.05) 0.13 (0.06) 0.13 (0.05)
SVC/RBF (100) 0.09 (0.05) 0.10 (0.05) 0.10 (0.05) 0.14 (0.05)
Table 6: Performance of different classification algorithms: AML dataset, inv(16) problem. Mean test set error (standard deviation) 
over 100 random splits of the original data into a training set (90%) and a test set (10%). Error is defined as average error per class, i.e. 
corresponding to assuming a prior probability of occurrence of a class of 50%. Classifiers were trained for 10, 20, 50, 100, 250, 500 and 
1000 probe sets selected by the variation filter; results shown here are for the number of probe sets resulting in the smallest average 
test set error over the four methods, indicated between brackets after the classifier name.
MAS dChip RMA GCRMA
Classifier NC (50) 0.01 (0.02) 0.02 (0.02) 0.01 (0.02) 0.02 (0.03)
(number of probe sets used) PAM (20) 0.01 (0.02) 0.01 (0.02) 0.01 (0.02) 0.01 (0.02)
LIKNON (10) 0.02 (0.03) 0.02 (0.03) 0.02 (0.02) 0.02 (0.02)
k-NN (50) 0.01 (0.02) 0.01 (0.02) 0.01 (0.02) 0.01 (0.02)
SVC/P (10) 0.02 (0.03) 0.02 (0.02) 0.02 (0.03) 0.02 (0.03)
SVC/RBF (10) 0.03 (0.02) 0.02 (0.02) 0.02 (0.02) 0.02 (0.02)BMC Bioinformatics 2006, 7:105 http://www.biomedcentral.com/1471-2105/7/105
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logical sample and the quality of RNA rather than on the
choice of the pre-processing procedure. However, we do
believe that an inverse relation exists, with the importance
of the method of normalization and expression summari-
zation increasing when the quality of the biological sam-
ple and the number of studied samples decrease.
Although we base this on a limited number of pre-
processing methods and data sets, we think that taking
into account more available methods will have no effect
on our conclusion.
Methods
Datasets
The two datasets used have been described before [19,22].
The first dataset consists of microarray measurements
taken on samples of 285 patients with acute myeloid
leukemia (AML), of whom blasts and mono-nuclear cells
were isolated from peripheral blood or bone marrow aspi-
rates. The samples were hybridized on Affymetrix HG-
U133A GeneChip microarrays. This dataset will be
referred to as the AML dataset; it is available on the Gene
Expression Omnibus website ([26], accession number
GSE1159). The second dataset contains gene-expression
data of 42 homogenized tumor tissues of the embryonal
central nervous system (CNS), hybridized on Affymetrix
HuGeneFL arrays. The dataset, referred to as the CNS data-
set, is available at [27].
Normalization and expression measurement
Both datasets were pre-processed with MAS, RMA,
GCRMA and dChip, resulting in eight different datasets.
MAS expression data combined with global scaling was
obtained from the MAS 5.0 software, provided by Affyme-
trix (Affymetrix Inc., Santa Clara, CA). dChip pre-process-
ing together with scaling of the data towards the median
average expression value per chip was applied using soft-
ware available from the authors [28]. RMA and GCRMA
pre-processing was performed together with quantile nor-
malization using the Bioconductor v2.0 library available
in the R software environment [29].
Real-time quantitative PCR (RT-PCR)
For the AML dataset only, a number of measured probe set
expression levels were compared to available RT-PCR
measurements of the corresponding genes on subsets of
the original dataset (with n varying between 208 and 277,
as indicated in Supp. Table 2 (see Additional file 1)).
Probe sets were selected for RT-PCR measurement based
on biological relevance to the study of leukemia; samples
were selected based on availability of material. Eligible
patients had a diagnosis of primary AML, confirmed by
cytological examination of blood and bone marrow. After
informed consent, bone marrow aspirates or peripheral
blood samples were taken at diagnosis. Blasts and mono-
nuclear cells were purified by Ficoll-Hypaque (Nygaard,
Oslo, Norway) centrifugation and cryopreserved. The
AML samples contained 80–100 percent blast cells after
thawing, regardless of the blast count at diagnosis.
After thawing, cells were washed once with Hanks bal-
anced salt solution. High quality total RNA was extracted
by lysis with guanidinium isothiocyanate followed by
cesium chloride gradient purification. RNA concentra-
tion, quality and purity were examined using the RNA
6000 Nano assay on the Agilent 2100 Bioanalyzer (Agi-
lent, Amstelveen, The Netherlands). None of the samples
Table 9: CNS dataset, MED problem.
MAS dChip RMA GCRMA
Classifier NC (1000) 0.04 (0.09) 0.03 (0.09) 0.03 (0.08) 0.07 (0.13)
(number of probe sets used) PAM (1000) 0.05 (0.10) 0.07 (0.13) 0.09 (0.14) 0.06 (0.13)
LIKNON (1000) 0.10 (0.12) 0.06 (0.11) 0.10 (0.13) 0.18 (0.18)
k-NN (500) 0.06 (0.11) 0.06 (0.12) 0.08 (0.12) 0.04 (0.10)
SVC/P (1000) 0.09 (0.12) 0.05 (0.11) 0.04 (0.09) 0.07 (0.12)
SVC/RBF (10) 0.17 (0.13) 0.16 (0.13) 0.17 (0.14) 0.14 (0.14)
Table 8: AML dataset, CCR problem.
MAS dChip RMA GCRMA
Classifier NC (1000) 0.34 (0.09) 0.34 (0.08) 0.33 (0.08) 0.35 (0.08)
(number of probe sets used) PAM (10) 0.29 (0.06) 0.30 (0.06) 0.30 (0.05) 0.30 (0.06)
LIKNON (20) 0.27 (0.08) 0.31 (0.07) 0.31 (0.08) 0.28 (0.07)
k-NN (20) 0.28 (0.07) 0.29 (0.06) 0.30 (0.06) 0.29 (0.07)
SVC/P (20) 0.28 (0.08) 0.31 (0.07) 0.31 (0.07) 0.28 (0.06)
SVC/RBF (20) 0.28 (0.05) 0.30 (0.04) 0.30 (0.04) 0.29 (0.04)BMC Bioinformatics 2006, 7:105 http://www.biomedcentral.com/1471-2105/7/105
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showed RNA degradation (28S/18S rRNA ratio ≥ 2) or
contamination by DNA.
cDNA was synthesized from 1ìg of RNA using random
hexamer priming, essentially as described [30]. cDNA pre-
pared from 50ng of RNA was used for all RT-PCR amplifi-
cations.
Real-time quantitative PCR amplification was performed
with the ABI PRISM 7700 sequence Detector (Applied
Biosystems, Nieuwerkerk aan den IJssel, Netherlands),
using 50 µL mix containing 20 µM deoxyribonucleoside
triphosphates (dNTPs; Amersham Pharmacia Biotech,
Roosendaal, Netherlands); 15 pmol forward and reverse
primer (Life Technologies); 3 mM MgCl2 (5 mM for the
reference gene porphobilinogen deaminase [PBGD]); 10
pmol probe (Eurogentec, Maastricht, Netherlands); 5 µL
10 × buffer A and 1.25 U AmpliTaq Gold (Applied Biosys-
tems). The primers and probe combinations for detection
of  EVI1  [EMBL:BX647613] [31], CEBPA  [Ref-
Seq:NM_004364.2] [32], TRKA [EMBL:M23102] [33] and
PBGD  [EMBL:AB162702] [33] have been described.
Primer and probe combinations used to determine the
expression of MEIS1  [EMBL:AB040810],  HOXA7
[EMBL:AJ005814],  PRDM1  [EMBL:AL358952], and
PRDM2 [EMBL:U23736] are listed in Supp. Table 1 (see
Additional file 1). Expression of HOXA9
[EMBL:BC006537],  GMCSF  [EMBL:X03021],  P8
[EMBL:AF135266] was measured with 1 × SYBR Green I
dye (Applied Biosystems). The primers used in the SYBR
Green reactions are listed in Supp. Table 1 (see Additional
file 1). The thermal cycling conditions included 10 min-
utes at 95°C followed by 45 cycles of denaturation for 30
seconds at 95°C and annealing/extension at 60°C for 60
seconds.
To quantify the relative expression levels of the various
genes in AML the Ct values were normalized for the
endogenous reference PBGD (∆Ct = Cttarget - CtPBGD) and
compared with a calibrator NBM cells from healthy vol-
unteers, using the ∆∆Ct method (∆∆Ct = ∆Ct AMLsample -
∆CtCalibrator). We used the ∆∆Ct value to calculate relative
expression (2-∆∆Ct).
A minimum threshold of 1 was applied, as well as log(2)
transformation [34]. Pearson correlation coefficients were
calculated between the RT-PCR data and the correspond-
ing microarray-data pre-processed by the different proce-
dures. Pearson correlation coefficients between data from
the different procedures were also calculated, for each
probe set present on the microarray.
Data transformation
For each probe set, the geometric mean m of all expression
values e over the different samples was calculated. The
level of expression for a particular sample was subse-
quently determined as log2(e)-log2(m). This transforma-
tion was applied to all datasets and only transformed data
was used for detection of differential expression, cluster
analysis and classification.
Differential expression
Tests for differential expression were performed on several
biologically relevant groups, by comparing samples from
a group to the remainder of the samples. Four groups were
tested in the AML dataset: (1) samples with a recurrent
mutation in the FLT3 gene (n = 78), (2) samples with
inversion of chromosome 16, (inv(16), n = 23), (3) sam-
ples with translocation of chromosomes 15 and 17
(t(15;17), n = 19) and (4) samples with translocation of
chromosomes 8 and 21 (t(8;21), n = 22). In the CNS data-
set, four groups were tested as well: (1) samples with
primitive neuro-ectodermal tumors (PNET, n  = 8), (2)
samples with medullablastomas (MED, n = 10), (3) sam-
ples with rhabdoid tumors (RHAB, n = 10) and (4) sam-
ples with malignant gliomas (GLIO, n = 10).
Student's t-test and Wilcoxon's rank sum test were applied
to each probe set [35]. The resulting p-values were
adjusted for multiple testing by Šidák step-down adjust-
ment to control the Family-Wise Error Rate or FWER [36].
The Significance Analysis of Microarrays (SAM) permuta-
tion algorithm (Excel-version 1.21, [37]), controlling the
False Discovery Rate (FDR), was also applied [23]. SAM
provides an estimate of the FDR known as a q-value.
Each test was applied and lists of probe sets, considered
significantly differentially expressed at an FWER or FDR of
5%, were retrieved. For all possible combinations (i.e.
MAS-dChip, MAS-RMA, MAS-GCRMA, dChip-RMA,
dChip-GCRMA and RMA-GCRMA) probe sets marked as
significantly differentially expressed by both methods
were counted. To be able to compare different combina-
tions, an overlap ratio R(A,B) was calculated between the
number of probe sets detected as differentially expressed
in both datasets A and B and the total number of unique
probe sets detected in the two datasets:
where p is the number of probe sets significant in both
datasets, a is the number of significant probe sets found in
dataset A and b is the number of significant probe sets
found in dataset B.
Cluster analysis
Subsets of n probe sets (for the AML dataset, n = 3000; for
CNS, n = 1000) were created by ranking probe sets by their
standard deviation over all samples, and selecting the top
RAB
p
ab
(,) =
+
2BMC Bioinformatics 2006, 7:105 http://www.biomedcentral.com/1471-2105/7/105
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n. Samples in all datasets (4 pre-processing methods) were
clustered using k-means clustering and hierarchical clus-
tering on both correlation distance matrices, in which the
distance between two samples x and y is defined as 1-ρxy;
and Euclidean distance matrices, as used in [19]. Hierar-
chical clustering was performed using single, average and
complete linkage. To be able to compare all methods and
datasets, the number of clusters was fixed to the expected
number of groups based on biological characteristics of
the patient population, which was 12 for the AML dataset
and 5 for the CNS dataset. To investigate the influence of
this setting, the AML dataset was also clustered into 2 and
20 clusters and the CNS dataset was clustered into 2 and
10 clusters, respectively. During each run of the k-means
algorithm it was randomly restarted 1000 times, retaining
the solution yielding minimum cluster within-scatter, in
an attempt to avoid local minima.
Clustering results were compared using the Jaccard index.
The Jaccard-index J(C1,C2) compares two clusterings C1
and C2 based on the number of similar sample pairs avail-
able in the clusters and results in a value between 0 (no
similar pairs) and 1 (all pairs are equal). It is estimated as
where n12 denotes the number of pairs of samples in the
same cluster in C1 and assigned to the same cluster in C2,
n1 denotes the number of pairs in the same cluster in C1,
but in different clusters in C2 and n2 denotes the number
of pairs in the same cluster in C2, but in a different cluster
in C1.
The raw Jaccard index should be interpreted in the light of
how stable C1  and  C2  actually are. If a clustering C,
obtained using a certain pre-processing method, changes
when one or a few samples are removed, it is to be
expected that using a different pre-processing method will
also have an impact. To estimate stability, for each pre-
processing method 100 pairs of random subsets each con-
taining 90% of the samples were clustered. Each individ-
ual subset was transformed as described and n = 3000 (or
n = 1000 for the CNS dataset) probe sets were selected
(these sets were 97.1% identical on average). In each pair,
both subsets were then clustered, and the Jaccard index
between these two clusterings was calculated using the
samples present in both subsets. This resulted in 100 Jac-
card indices, giving an impression of the variability due to
transformation and subset selection. Finally, normal dis-
tributions were fitted to the 100 Jaccard indices found.
For a Jaccard index resulting from a comparison between
two pre-processing methods M1 and M2, the cumulative
distribution function (CDF) of the normal distribution
for both pre-processing methods is used to arrive at two
stability-normalized Jaccard indices J1
SN and J2
SN. Figure
3A illustrates this. A value of 0.5 for Ji
SN (in Figure 3A
obtained at a Jaccard index of 0.48 for MAS or 0.62 for
RMA) indicates that differences between pre-processing
methods fall well within the range of clustering variability
for pre-processing method Mi; values higher than that
indicate that clustering differences due to pre-processing
are in fact smaller than the average differences between
clusterings on subsampled datasets. Although the notion
of stability has been used before in clustering (e.g. [38]),
we believe this normalized index to be novel.
Note that for the k-means algorithm, stability-normalised
Jaccard indices are displayed in Figures 3B and 3C as mean
and standard deviation over 10 runs of the algorithm,
each run the result of 1000 restarts (see above).
Classification
Three two-class problems were defined on the AML data-
set: (1) samples with inversion of chromosome 16
(inv(16) vs. all others, (2) samples with a mutation in the
FLT3-gene vs. all others and (3) samples that showed con-
tinuous complete remission (CCR) vs. samples that did
not. These problems were selected in increasing order of
expected difficulty. In the case of the CNS dataset, four
two-class problems (PNET vs. others, MED vs. others,
RHAB vs. others and GLIO vs. others) were defined. A
number of classifiers were trained on probe set subsets of
increasing size (n = 10, 20, 50, 100, 200, 500, 1000).
Probe sets were selected here using a signal-to-noise ratio
(SNR) variation filter, i.e. |µ1-µ2|/√(σ1
2 + σ2
2) on the train-
ing set. Classifiers used were nearest centroid (NC), near-
est shrunken centroid (PAM) [39], LIKNON [40], k-
nearest neighbour (k-NN), support vector classifier with
polynomial kernel of degree d (SVC-P) and radial basis
function kernel of width σ (SVC-R) [41]. The parameters
k, d and σ were optimised by performing cross-validation
(k: leave-one-out; d, σ : 10-fold) on the training set only.
Both PAM and LIKNON provide their own feature selec-
tion algorithm, which selects the optimal feature set
within the set selected by the variation filter. In a single
experiment, 90 percent of the samples (randomly
selected) were used to train a classifier after which the clas-
sifier was tested on the remaining 10 percent. This experi-
ment was repeated 100 times, resulting in an average
performance and a standard deviation.
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MED Medullablastoma
GLIO Malignant glioma
RHAB Rhabdoid tumors
SAM Significance analysis of microarrays
CDF Cumulative distribution function
CCR Continuous complete remission
PAM Prediction analysis of microarrays
k-NN k-Nearest neighbour
NC Nearest centroid
SVC-P Support vector classifier with polynomial kernel of
degree d
SVC-R Support vector classifier with radial basis function
kernel of width σ
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